Poly Medicure
Poly Medicure Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: fundraise.
The short version
The company aims to double its revenue by 2030, implying an 18% compounded annual growth over four years, with about 80% organic and 20% inorganic growth. Poly Medicure aims to double revenue by FY2030 with a CAGR of about 18%, comprising approximately 14-15% organic growth and 3-4% from acquisitions. - Stand-alone revenue guidance for FY27 is INR1,900-2,000 crores with domestic growth over 20% and international growth over 15%. - Stand-alone EBITDA margin expected between 25% to 27%, with consolidation margins slightly lower (23%-25%) due to acquisition integration. - Q1 EBITDA margin was at 28%, slightly above guidance, helped by price hikes and inventory adjustments. - Operating leverage is present but mixed with fixed and variable employee costs; no definitive long-term percentage given. - Export growth drivers include Europe (17% organic growth in Q1) and Southeast Asia; Middle East expected to revive once logistical issues resolve. - New product pipeline includes approx.
From Poly Medicure's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company aims to double its revenue by 2030, implying an 18% compounded annual growth over four years, with about 80% organic and 20% inorganic growth.
- Domestic business is expected to grow over 20%, and international business over 15% for FY27.
- Europe and Southeast Asia markets are key growth drivers currently, with Europe showing 17%+ growth in Q1.
- Middle East orders are strong but delayed due to logistics; growth expected once regional situation improves.
- Approximately 25 new products are in the pipeline for CE marking, expected to launch in the next 3-4 months, augmenting export growth.
- Renal segment faced a slight de-growth (~3% in Q1) due to competition and pricing pressures but anticipates recovery post government antidumping actions.
- Acquired companies (PendraCare and Citieffe) expected to grow in mid to high single digits, aiming for mid-teen growth with synergies over time.
- Overall inorganic growth expected at 3%-4%, organic around 14%-15%.
Profitability & Margins
See what Poly Medicure said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Board has allocated funds for expansion both organic and inorganic, including the recent acquisition in Brazil to expand direct sales presence.
- Focus on technologies around three critical businesses: cardiology, oncology, and orthopedics, and adjacent technologies.
- Capex planned at two plants under construction: one in Faridabad and one in Noida for medical devices.
- Expected capex spend for FY27 is between INR 200 crores to INR 225 crores.
- Manufacturing process shifts from acquired companies (PendraCare and Citieffe) to India are underway but subject to regulatory approvals.
- Strategic funds of about INR 850 crores in cash reserved for these growth initiatives and acquisitions.
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Poly Medicure said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Middle East order book is described as "pretty strong," indicating robust demand.
- However, there is a current inability to ship products to the Middle East due to logistics and infrastructure bottlenecks related to the ongoing West Asia crisis.
- Orders are piling up at ports or in factories because of disrupted shipping schedules, especially container shortages for Middle East ports.
- Demand from customers remains intact despite these shipping and logistical challenges.
- There is optimism that once the geopolitical and logistical situation improves, normalcy will return, and the backlog of orders will be fulfilled.
Poly Medicure — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹535 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Poly Medicure Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Healthcare Equipment & Supplies this season
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental Ltd (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
- Prevest Denpro Ltd (Q1 FY27)
Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…
- Vasa Denticity Ltd (Q1 FY27)
Average order value increased by about 27% largely due to higher ticket-size products; order volume growth was around 8% (Page 6). Key concall takeaways from…
Frequently Asked Questions
What were Poly Medicure Q1 FY27 results?
The company aims to double its revenue by 2030, implying an 18% compounded annual growth over four years, with about 80% organic and 20% inorganic growth. Poly Medicure aims to double revenue by FY2030 with a CAGR of about 18%, comprising approximately 14-15% organic growth and 3-4% from acquisitions. - Stand-alone revenue guidance for FY27 is INR1,900-2,000 crores with domestic growth over 20% and international growth over 15%. - Stand-alone EBITDA margin expected between 25% to 27%, with consolidation margins slightly lower (23%-25%) due to acquisition integration. - Q1 EBITDA margin was at 28%, slightly above guidance, helped by price hikes and inventory adjustments. - Operating leverage is present but mixed with fixed and variable employee costs; no definitive long-term percentage given. - Export growth drivers include Europe (17% organic growth in Q1) and Southeast Asia; Middle East expected to revive once logistical issues resolve. - New product pipeline includes approx.
What is Poly Medicure share price analysis?
Poly Medicure currently shows a below-average growth signal. The stock trades at a P/E of 54.5 with a market cap of ₹17,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure planning capital expenditure?
Board has allocated funds for expansion both organic and inorganic, including the recent acquisition in Brazil to expand direct sales presence.
Keep Poly Medicure on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.